Glucose

Glucose is a sterile aqueous solution for injection containing glucose monohydrate as the active ingredient. It is supplied in an unspecified strength and is intended for intravenous administration. The product is classified as an excipient and is used primarily in parenteral nutrition and the treatment of hypoglycemia. It complies with European Union pharmaceutical standards. It is packaged in single‑use vials for safe handling and is compatible with standard infusion sets.

Glucose solution for injection is employed in clinical settings to address specific metabolic and nutritional needs.

- Management of acute hypoglycemia in patients unable to take oral glucose. - Provision of carbohydrate calories as part of total parenteral nutrition (TPN). - Support during peri‑operative fasting when oral intake is not possible. - Correction of low blood glucose levels during insulin therapy or glucose‑lowering procedures. - Dilution medium for certain intravenous medications requiring a compatible carbohydrate carrier.

Intravenous administration of glucose may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common: - Transient hyperglycemia or elevated blood glucose levels. - Local irritation or pain at the injection site. - Nausea or mild gastrointestinal discomfort. - Fluid overload in patients with compromised cardiac function. - Headache or dizziness related to rapid glucose changes.

Serious: - Severe hyperglycemia leading to osmotic diuresis or ketoacidosis in susceptible patients. - Allergic reactions such as rash, urticaria, or anaphylaxis. - Electrolyte disturbances, particularly hypokalemia, secondary to rapid glucose shifts. - Venous thrombosis or phlebitis at the infusion site. - Severe hyperglycemia leading to osmotic diuresis or ketoacidosis in susceptible patients.

When prescribing or administering glucose solution for injection, healthcare professionals should observe several precautionary measures to ensure patient safety.

- Assess baseline blood glucose and adjust infusion rate accordingly. - Monitor serum electrolytes, especially potassium, during and after infusion. - Use caution in patients with renal or hepatic impairment due to altered glucose metabolism. - Avoid rapid infusion in individuals at risk for fluid overload or heart failure. - Ensure sterility by using single‑use vials and discarding any contaminated equipment. - Document infusion details, including concentration and total volume administered. - Verify compatibility with co‑administered intravenous drugs before mixing.

Glucose solution for injection can interact with other medications or clinical conditions, influencing therapeutic outcomes.

Avoid: - Concurrent high‑dose insulin therapy without close glucose monitoring, which may precipitate severe hypoglycemia. - Co‑administration with potassium‑sparing diuretics in patients prone to hyperglycemia, increasing risk of electrolyte imbalance. - Use with certain radiographic contrast agents that may exacerbate hyperglycemia.

Use with caution: - Intravenous lipid emulsions, as combined caloric load may require adjustment of total nutrient provision. - Catecholamine infusions (e.g., epinephrine) that can raise blood glucose levels, necessitating tighter monitoring. - Medications that affect glucose metabolism such as glucocorticoids, requiring individualized dosing.